-transparent.png){kind=logo}
Thyroid stimulating antibodies (TSAb) and thyrotropin binding inhibiting immunoglobulins (TBII) were measured in 32 patients with Graves' disease who had been in remission for at least two years after treatment was been stopped. Seventeen patients had been treated with antithyroid drugs, and 15 patients with 131Iodine. In the first group 3 of 17 patients had TSAb and one TBII, whereas in the second group 4 of 15 patients had TSAb and two TBII. One patient from each group had inhibiting TSAb. During the follow-up one patient from each group relapsed, whereas 5 patients from the second group developed myxoedema. No relationship between the clinical outcome and TSAb and TBII was found.
H Bliddal, and
K Bech, and
C Kirkegaard
October 1986,
Klinische Wochenschrift,
H Bliddal, and
K Bech, and
C Kirkegaard
August 1974,
Lancet (London, England),
H Bliddal, and
K Bech, and
C Kirkegaard
March 1977,
Clinical endocrinology,
H Bliddal, and
K Bech, and
C Kirkegaard
January 2006,
Endokrynologia Polska,
H Bliddal, and
K Bech, and
C Kirkegaard
October 1986,
Medicina clinica,
H Bliddal, and
K Bech, and
C Kirkegaard
January 1983,
Acta endocrinologica. Supplementum,
H Bliddal, and
K Bech, and
C Kirkegaard
June 1986,
Endocrinologia japonica,
H Bliddal, and
K Bech, and
C Kirkegaard
November 2011,
Ophthalmology,
H Bliddal, and
K Bech, and
C Kirkegaard
June 1995,
Endocrine journal,
H Bliddal, and
K Bech, and
C Kirkegaard
June 1986,
Journal of endocrinological investigation,
